Evaluation of Pharmacologic Treatments for H1 Antihistamine–Refractory Chronic Spontaneous Urticaria

医学 梅德林 奇纳 抗组胺药 随机对照试验 科克伦图书馆 安慰剂 内科学 数据提取 荟萃分析 临床试验 物理疗法 儿科 心理干预 替代医学 精神科 药理学 病理 法学 政治学
作者
Surapon Nochaiwong,Mati Chuamanochan,Chidchanok Ruengorn,Ratanaporn Awiphan,Napatra Tovanabutra,Siri Chiewchanvit
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:157 (11): 1316-1316 被引量:25
标识
DOI:10.1001/jamadermatol.2021.3237
摘要

The comparative benefits and harms of all available treatments for H1 antihistamine-refractory chronic spontaneous urticaria (CSU) have not been established.To evaluate different treatment effects of pharmacologic treatments among patients with H1 antihistamine-refractory CSU.Searches were conducted of MEDLINE, Embase, PubMed, Cochrane Library, Web of Science, Scopus, and CINAHL from inception to April 19, 2021, with no language restrictions. Gray literature from Google Scholar, ongoing trial registers, and preprint reports was added to the searches of electronic databases.Randomized clinical trials using validated measurement tools that investigated the benefits and harms of pharmacologic treatments among adolescent or adult patients with CSU who had an inadequate response to H1 antihistamines were screened for inclusion independently by 2 investigators.Two investigators independently extracted study data according to the predefined list of interests. A random-effects model was used to calculate the network estimates reported as standardized mean differences and odds ratios with corresponding 95% CIs.The primary outcomes that reflect the patient's perspective included changes in urticaria symptoms from baseline and unacceptability of treatment (all-cause dropouts).Twenty-three randomized clinical trials with 2480 participants that compared 18 different interventions or dosages and placebo were included. The standardized mean differences for change in urticaria symptoms were -1.05 (95% CI, -1.37 to -0.73) for ligelizumab, 72 mg; -1.07 (95% CI, -1.39 to -0.75) for ligelizumab, 240 mg; -0.77 (95% CI, -0.91 to -0.63) for omalizumab, 300 mg; and -0.59 (95% CI, -1.10 to -0.08) for omalizumab, 600 mg. No significant differences in treatment unacceptability were observed. With respect to benefits and harms, the network estimates illustrated that the most efficacious treatments were achieved with ligelizumab, 72 or 240 mg (large beneficial effect) and omalizumab, 300 or 600 mg (moderate beneficial effect).The findings in this meta-analysis suggest that the biologic agents ligelizumab, 72 or 240 mg, and omalizumab, 300 or 600 mg, can be recommended as effective treatments for patients with CSU who have had an inadequate response to H1 antihistamines. Head-to-head trials with high methodologic quality and harmonized design and outcome definitions are needed to help inform subsequent international guidelines for the management of CSU.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
灵魂发布了新的文献求助10
2秒前
高挑的若剑完成签到,获得积分10
3秒前
mt13完成签到,获得积分10
3秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
yar应助科研通管家采纳,获得10
4秒前
田様应助科研通管家采纳,获得10
4秒前
科研通AI5应助科研通管家采纳,获得10
4秒前
共享精神应助科研通管家采纳,获得10
4秒前
4秒前
Owen应助科研通管家采纳,获得10
4秒前
4秒前
yar应助科研通管家采纳,获得10
4秒前
ll应助科研通管家采纳,获得10
4秒前
ll应助科研通管家采纳,获得10
4秒前
byebyettt完成签到 ,获得积分10
5秒前
量子星尘发布了新的文献求助10
5秒前
6秒前
情怀应助wukang采纳,获得10
8秒前
科目三应助lei029采纳,获得10
10秒前
旧辞完成签到,获得积分10
11秒前
冰凉完成签到,获得积分10
13秒前
木子完成签到,获得积分10
14秒前
16秒前
18秒前
悠悠我心完成签到,获得积分20
18秒前
wukang给wukang的求助进行了留言
19秒前
大个应助风中无血采纳,获得10
22秒前
人生如梦应助追寻天亦采纳,获得10
22秒前
25秒前
李健的小迷弟应助N_N采纳,获得10
27秒前
苏航发布了新的文献求助10
28秒前
29秒前
风中无血发布了新的文献求助10
33秒前
昏睡的绍辉完成签到,获得积分10
35秒前
36秒前
搜集达人应助daxiong采纳,获得10
39秒前
量子星尘发布了新的文献求助10
40秒前
40秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975378
求助须知:如何正确求助?哪些是违规求助? 3519775
关于积分的说明 11199621
捐赠科研通 3256067
什么是DOI,文献DOI怎么找? 1798124
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305